SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is currently trending due to a rumored $53 billion buyout offer from Stripe and Advent International, which has sparked intense debate among investors over whether the proposed price is an opportunistic lowball or a necessary catalyst for a turnaround. While many long-term holders argue that the company's strong cash flow and market position warrant a significantly higher valuation, day traders and speculators are actively debating whether to capitalize on the resulting volatility or wait for a potential bidding war.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing significant volatility as investors debate the impact of heavy AI infrastructure spending and mounting debt against the company's long-term cloud backlog and strategic enterprise position. The community remains deeply polarized, with some bulls viewing the recent sell-off as a generational buying opportunity while others express frustration over management's lack of communication amid the ongoing downtrend.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group Inc. is experiencing extreme volatility following unconfirmed rumors of a potential bankruptcy filing or take-private deal, which the company has since formally denied as false. Investors are actively debating the legitimacy of the news, the company's long-term liquidity, and whether the drastic price swing served as a tactical manipulation for short sellers.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is surging as investors react to a significant follow-on production order for its FOX-XP wafer-level burn-in system from a major silicon photonics customer, signaling a shift from product evaluation into large-scale production. The community is actively debating the stock's valuation relative to its revenue growth, with some traders highlighting the potential for a short squeeze while others urge caution regarding long-term fundamentals and potential share dilution.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending following the launch of its AI-native RAN platform in partnership with NVIDIA, which aims to double network capacity and improve efficiency. Despite this positive catalyst, the stock faces volatility as community members debate whether recent price drops are institutional manipulation intended to shake out retail investors before upcoming earnings.

SK hynix, Inc. engages in the manufacture and sale of semiconductor products. Its products include dynamic random access memory, flash memory, complementary metal oxide semiconductor image sensor, and others. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is experiencing significant volatility and trading momentum following its recent Nasdaq debut, with investors actively debating the impact of the ADR's price premium relative to Korean shares. Community discussion is heavily focused on the stock's critical role in the AI hardware supply chain and the launch of new leveraged ETFs and options, which traders are using to capitalize on the stock's rapid price swings.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML Holding is experiencing significant market interest driven by its role as a critical bottleneck in the AI semiconductor supply chain, with community sentiment boosted by positive analyst revisions and ongoing strategic collaborations. Investors are actively discussing the company's indispensable position in Extreme Ultraviolet (EUV) lithography and its long-term growth potential amidst global efforts to expand advanced chip manufacturing capacity.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Celcuity is seeing significant investor attention following the successful Phase 3 VIKTORIA-1 trial results, which demonstrated that its lead oncology asset, gedatolisib, achieved primary endpoints in treating HR+/HER2- breast cancer. The community is actively debating the stock's valuation as it transitions to a commercial-stage company, focusing on potential FDA approval timelines and the likelihood of becoming a target for a pharmaceutical acquisition.

Conagra Brands, Inc. engages in the manufacture and sale of processed and packaged foods. It operates through the following segments: Grocery and Snacks, Refrigerated and Frozen, International, and Foodservice. The Grocery and Snacks segment includes branded, and shelf stable food products sold in various retail channels in the United States. The Refrigerated and Frozen segment is composed of branded, and temperature-controlled food products sold in various retail channels in the United States. The International segment offers branded food products in various temperature states, sold in various retail and foodservice channels outside of the United States. The Foodservice segment focuses on branded and customized food products, including meals, entrees, sauces, and a variety of custom-manufactured culinary products packaged for sale to restaurants and other foodservice establishments in the United States. The company was founded by Alva Kinney and Frank Little in 1919 and is headquartered in Chicago, IL.

Conagra Brands Inc

Conagra Brands is under significant selling pressure as investors react to disappointing fiscal guidance and a 50% dividend cut intended to bolster the company's turnaround efforts. The community is actively debating the stock's long-term defensive value at its current price levels, with many traders looking for an accumulation point following the sharp market reaction.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson shares are facing selling pressure despite recent quarterly earnings beats and raised guidance, as investors rotate away from healthcare defensives and digest ongoing legal overhangs related to talc litigation. While the company continues to see strong demand in its MedTech and Innovative Medicine segments, community sentiment is divided between those positioning for a long-term recovery and traders wary of short-term technical weakness and sector rotation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%

The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in Exagen (XGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Exagen (XGN) Q1 2026 Earnings Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

Exagen Q1 Earnings Call Highlights

The New Spec Supercycle

Momentum traders are once again crowding into emerging growth sectors as artificial intelligence infrastructure, defense modernization, advanced medical technologies, and digital asset finance combine to create one of the market’s most aggressive speculative environments in years. Several names touched new 52-week highs Monday morning alongside major technology leaders including NVIDIA (NASDAQ:NVDA). $ODYS, $KBLB, $DGXX, $BW, $XGN, $MEHA, $NVDA

Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates

Exagen (XGN) delivered earnings and revenue surprises of +29.17% and +4.57%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

AtriCure (ATRC) Reports Break-Even Earnings for Q1

AtriCure (ATRC) delivered earnings and revenue surprises of +100.00% and +1.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates

Zimmer (ZBH) delivered earnings and revenue surprises of +12.57% and +1.84%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Exagen Inc. (NASDAQ:XGN) Sees Large Decrease in Short Interest

Exagen Inc. (NASDAQ:XGN - Get Free Report) was the recipient of a large decline in short interest in April. As of April 15th, there was short interest totaling 729,740 shares, a decline of 52.5% from...

Exagen Inc. (NASDAQ:XGN) Given Average Recommendation of "Moderate Buy" by Analysts

Exagen Inc. (NASDAQ:XGN - Get Free Report) has been given an average recommendation of "Moderate Buy" by the ten research firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average 1...

Exagen (NASDAQ:XGN) Cut to "Sell" at Wall Street Zen

Wall Street Zen downgraded shares of Exagen from a "hold" rating to a "sell" rating in a report on Sunday...

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.

Exagen Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$4.28
Prev Close	$4.09
Open	$4.10
Dividend Yield	0.00%
50-Day Moving Average	$4.23
Beta	1.36
Avg. Volume	293,705.86
PE Ratio	-4.63

52-Week High	$12.23
52-Week Low	$2.59
Market Capitalization	$98.81M
EPS (Annual)	-$0.9254
Price to Book	6.83
Revenue Per Employee	$308,217.59

Feed

News

Sentiment

Earnings

Fundamentals

Info

XGNExagen Inc

Latest XGN News